Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

Weight loss drugs could be a gamechanger for women with a common hormonal disorder By Annika Kim Constantino, CNBC • Published July 20, 2025 • Updated on July 21, 2025 at 1:33 pm ...